SCHEMBL2886872

SCHEMBL2886872

CCOC(=O)c1ncc2c(cc(-c3ccc(Cl)cc3)n2Cc2ccc3c(c2)OCO3)c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.50
LMNA P02545 4/20 0.50
MAPT P10636 4/20 0.50
HPGD P15428 3/20 0.50
CYP19A1 P11511 1/20 0.47
HSD17B10 Q99714 4/20 0.43
ALOX15 P16050 3/20 0.43
TSHR P16473 3/20 0.43
GAA P10253 2/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
CYP3A4 P08684 2/20 0.43
ABCB11 O95342 1/20 0.43
CYP1A2 P05177 1/20 0.43
ADRA2A P08913 1/20 0.43
CYP2D6 P10635 1/20 0.43
CHRM1 P11229 1/20 0.43
TBXA2R P21731 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2887960 0.92 SMN1; SMN2 (0.51) SMN1; SMN2LMNAMAPTHPGDCYP19A1
SCHEMBL2889328 0.87 SMN1; SMN2 (0.44) SMN1; SMN2LMNAMAPTHPGDCYP19A1
SCHEMBL2889255 0.85 SMN1; SMN2 (0.47) SMN1; SMN2LMNAMAPTHPGDCYP19A1
SCHEMBL2881020 0.84 EGLN1 (0.54) SMN1; SMN2MAPTHPGDHSD17B10ALOX15
SCHEMBL2887137 0.83 SMN1; SMN2 (0.46) SMN1; SMN2LMNAMAPTHPGDCYP19A1
SCHEMBL2883552 0.81 LMNA (0.53) SMN1; SMN2LMNAMAPTHPGDCYP19A1
SCHEMBL2888946 0.76 EGLN1 (0.60)
SCHEMBL2886803 0.76 CYP19A1 (0.43) SMN1; SMN2LMNAMAPTHPGDCYP19A1
SCHEMBL2887809 0.74 CYP19A1 (0.42) SMN1; SMN2LMNAMAPTHPGDCYP19A1
SCHEMBL20379069 0.72 LMNA (0.53) SMN1; SMN2LMNAMAPTHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
EP-2016078-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2009-01-21 EP disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed
WO-2007115315-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 SMN1; SMN2 3919/4885LMNA 4255/4885MAPT 2965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.